Incretin hormones and the satiation signal
Research output: Contribution to journal › Journal article › Research › peer-review
Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.
|Journal||International journal of obesity (2005)|
|Number of pages||8|
|Publication status||Published - Sep 2013|
- Animals, Eating, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Humans, Hyperglycemia, Hypoglycemic Agents, Incretins, Obesity, Peptides, Receptors, Glucagon, Satiation, Signal Transduction, Venoms, Weight Loss